1T6-220 study help - Switched Ethemet Network Analysis and Troubleshooting Updated: 2023

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.

The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.

The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don’t have that disease.

Experts have known for years that losing weight can Improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.

The obesity drug Wegovy can reduce the risk of severe heart problems by 20%, a pivotal study finds, paving the way for applications far beyond weight loss.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

The results of the large clinical trial were presented Saturday at the American Heart Association conference in Philadelphia and published in the New England Journal of Medicine.

The research, paid for by Wegovy and Ozempic maker Novo Nordisk, enrolled over 17,600 people from 41 countries.

Patients were 45 years or older and had a preexisting cardiovascular disease and a body-mass index of 27 or greater — but no history of diabetes.

Half the patients got weekly injections of Wegovy or a placebo shot — with participants tracked for more than three years on average.

569, or 6.5%, of those who received the drug experienced a heart attack or stroke or died from a heart-related cause, compared with 701, or 8%, of those who had the dummy shot.

The participants on Wegovy lost around 10% of their weight on average and kept those pounds off throughout the trial.

Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles, noted that the Wegovy patients also saw improvement in their inflammation, cholesterol, blood sugars and blood pressure.

“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who did not author the study.

It’s unclear whether those results are from losing weight or the drug itself.

Novo Nordisk has requested the Food and Drug Administration include heart benefits on Wegovy’s label, like on Ozempic’s label.

Wegovy is a high-dose version of Ozempic, which has been shown to decrease the risk of serious heart issues in people with diabetes. This new study is groundbreaking for focusing on people without diabetes.

Participants of the latest study did report major side effects, which have dogged these types of obesity medications from the outset.

Nearly 17% of people on Wegovy discontinued the treatment because of “adverse events,” such as nausea, vomiting, diarrhea, while 8% of the placebo group dropped out.

“Ozempic finger,” “Ozempic burp,” “Ozempic butt,” “Ozempic face” and weird dreams about celebrities are among the downsides that have been reported by users in recent months.

There are also hefty price tags — monthly costs range from about $1,300 for Wegovy to about $1,000 for Eli Lilly’s Zepbound, a version of the diabetes medication Mounjaro, approved last week by the FDA for weight control.

These drugs are often not covered by private health insurance — or there are strict preauthorization requirements if they are.

With Post wires

STRAWBERRIES could help prevent dementia and depression for the overweight in middle-age.

A daily portion of the fruit for 12 weeks improved mood and reduced problems relating to memory and mental health, a study found.

1

Researchers hope their findings could assist in the prevention of dementia, which currently has no known cure and affects one in 11 over the age of 65 in the UK.

Professor Robert Krikorian, of the University of Cincinnati, in the US, said: “Dementia is a general term that includes many different diseases, all without remedies.

“It is not clear when or if effective therapy will be available; prevention and mitigation through dietary and lifestyle choices is currently the best approach we have.”

He added: “Our findings can likely be attributed to the anti-inflammatory actions of the anthocyanins found in strawberries.

“We wanted to work with a middle-aged, overweight population as dementia is a condition that is believed to develop over a period of decades.

“Furthermore, inflammation is likely a contributing factor related to metabolic disorders such as obesity, pre-diabetes and type 2 diabetes.”

Strawberries are important for maintaining a healthy diet, as they provide 100 per cent of the recommended daily vitamin C amount in a single one cup serving.

They also contain heart-healthy nutrients.

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.

The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.

The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don't have that disease.

Experts have known for years that losing weight can Improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.

“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.

In the U.S., there are about 6.6 million people like those tested in the study, experts said.

The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy's label, like on Ozempic's.

The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.

The study found that 569, or 6.5%, of those who got the drug versus 701, or 8%, of those who received the dummy shot had a heart attack or stroke or died from a heart-related cause. That’s an overall reduction of 20% in the risk of those outcomes, the researchers reported.

The drop appeared to be fueled primarily by the difference in heart attacks, but the number of serious health complications reported were too small to tell whether the individual outcomes were caused by the drug or by chance.

Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%.

The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study, before participants lost much weight.

“It means to me that it's more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.

Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted.

About a third of all study volunteers reported serious side effects. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea and other stomach-related problems.

Nearly three-quarters of participants were men and nearly 84% were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.

Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly's Zepbound, a version of the diabetes drug Mounjaro, for weight control.

Both carry high price tags — monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. And both have been in shortage for months, with manufacturers promising to boost supplies.

The medications are often not covered by private health insurance or subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. But drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pay for the drugs.

Results from the latest study and others that show the obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.

That approach "may end up being relevant here,” he said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20 percent in a large, international study that experts say could change the way doctors treat certain heart patients.

The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.

The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don’t have that disease.

WATCH: Patients say drugs like Ozempic help with ‘food noise.’ Here’s what that means

Experts have known for years that losing weight can Improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.

“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.

In the U.S., there are about 6.6 million people like those tested in the study, experts said.

The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy’s label, like on Ozempic’s.

The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.

The study found that 569, or 6.5 percent, of those who got the drug versus 701, or 8 percent, of those who received the dummy shot had a heart attack or stroke or died from a heart-related cause. That’s an overall reduction of 20 percent in the risk of those outcomes, the researchers reported.

The drop appeared to be fueled primarily by the difference in heart attacks, but the number of serious health complications reported were too small to tell whether the individual outcomes were caused by the drug or by chance.

Study volunteers who took Wegovy lost about 9 percent of their weight while the placebo group lost less than 1 percent.

The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study, before participants lost much weight.

“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.

Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted.

About a third of all study volunteers reported serious side effects. About 17 percent in the Wegovy group and about 8 percent in the comparison group left the study, mostly because of nausea, vomiting, diarrhea and other stomach-related problems.

Nearly three-quarters of participants were men and nearly 84 percent were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.

Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, a version of the diabetes drug Mounjaro, for weight control.

Both carry high price tags — monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. And both have been in shortage for months, with manufacturers promising to boost supplies.

The medications are often not covered by private health insurance or subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. But drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pay for the drugs.

Results from the latest study and others that show the obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.

That approach “may end up being relevant here,” he said.

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.

The research is the first to document that an obesity medication can not only pare pounds but also safely prevent a heart attack, stroke, or a heart-related death in people who already have heart disease – but not diabetes.

The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don’t have that disease.

Experts have known for years that losing weight can Improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.

“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.

In the U.S., there are about 6.6 million people like those tested in the study, experts said.

The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy’s label, like on Ozempic’s.

The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher, and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.

The study found that 569, or 6.5%, of those who got the drug versus 701, or 8%, of those who received the dummy shot had a heart attack or stroke or died from a heart-related cause. That’s an overall reduction of 20% in the risk of those outcomes, the researchers reported.

The drop appeared to be fueled primarily by the difference in heart attacks, but the number of serious health complications reported was too small to tell whether the individual outcomes were caused by the drug or by chance.

Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%.

The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure, and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study before participants lost much weight.

“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.

Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted.

About a third of all study volunteers reported serious side effects. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea, and other stomach-related problems.

Nearly three-quarters of participants were men and nearly 84% were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.

Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, a version of the diabetes drug Mounjaro, for weight control.

Both carry high price tags – monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. And both have been in shortage for months, with manufacturers promising to boost supplies.

The medications are often not covered by private health insurance or are subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. But drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pay for the drugs.

Results from the latest study and others that show that obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.

That approach “may end up being relevant here,” he said.

« Previous

Next »